Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Gross Margin (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Gross Margin for 17 consecutive years, with 69.97% as the latest value for Q4 2025.

  • Quarterly Gross Margin fell 168.0% to 69.97% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 69.93% through Dec 2025, up 4.0% year-over-year, with the annual reading at 69.93% for FY2025, 4.0% up from the prior year.
  • Gross Margin for Q4 2025 was 69.97% at Myriad Genetics, roughly flat from 69.91% in the prior quarter.
  • The five-year high for Gross Margin was 96.99% in Q2 2021, with the low at 33.24% in Q4 2022.
  • Average Gross Margin over 5 years is 69.36%, with a median of 69.98% recorded in 2023.
  • The sharpest move saw Gross Margin tumbled -3828bps in 2022, then surged 2994bps in 2024.
  • Over 5 years, Gross Margin stood at 71.52% in 2021, then tumbled by -54bps to 33.24% in 2022, then increased by 25bps to 41.71% in 2023, then surged by 72bps to 71.65% in 2024, then dropped by -2bps to 69.97% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 69.97%, 69.91%, and 71.23% for Q4 2025, Q3 2025, and Q2 2025 respectively.